Jan 2019 $30 M Private placement after listing $10 to $50 million 1
Antigenics Inc /de/: Private sale, Jan 2019 × Investors in this round 1 investor had bought by the notice of Feb 1, 2019: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $30 M of $30 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Alex R. Duncan · Executive Officer Christian R. Cortis · Executive Officer Christine R. Klaskin · Executive Officer Evan R. Kearns · Executive Officer Garo H. Armen · Executive Officer, Director Jennifer R. Buell · Executive Officer Ozer R. Baysal · Executive Officer Allison R. Jeynes-Ellis · Director Brian H. Corvese · Director Timothy R. Wright · Director Ulf H. Wiinberg · Director Wadih H. Jordan · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Evan Kearns, Vice President and General Counsel. Source: SEC Form D, newest notice filed Feb 1, 2019. Read the notice at the SEC .
equity SEC Oct 2018 $40 M Private placement after listing $10 to $50 million 2
Antigenics Inc /de/: Private sale, Oct 2018 × Investors in this round 2 investors had bought by the notice of Oct 25, 2018: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $40 M of $40 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Alex R. Duncan · Executive Officer Christian R. Cortis · Executive Officer Christine R. Klaskin · Executive Officer Evan R. Kearns · Executive Officer Garo H. Armen · Executive Officer, Director Jennifer R. Buell · Executive Officer Ozer R. Baysal · Executive Officer Brian H. Corvese · Director Timothy R. Wright · Director Ulf H. Wiinberg · Director Wadih H. Jordan · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Evan Kearns, Vice President and General Counsel. Source: SEC Form D, newest notice filed Oct 25, 2018. Read the notice at the SEC .
equity SEC Feb 2017 $60 M Private placement after listing $50 to $250 million 1
Antigenics Inc /de/: Private sale, Feb 2017 × Investors in this round 1 investor had bought by the notice of Mar 1, 2017: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $60 M of $60 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Christine M. Klaskin · Executive Officer Garo H. Armen · Executive Officer, Director Karen H. Valentine · Executive Officer Ozer M. Baysal · Executive Officer Robert B. Stein · Executive Officer Brian H. Corvese · Director Shahzad H. Malik · Director Shalini H. Sharp · Director Timothy H. Wright · Director Ulf H. Wiinberg · Director Wadih H. Jordan · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Karen H. Valentine, Chief Legal Officer and General Counsel. Source: SEC Form D, newest notice filed Mar 1, 2017. Read the notice at the SEC .
equity SEC Dec 2015 $7 M Private placement after listing $2 to $10 million 17
Antigenics Inc /de/: Private sale, Dec 2015 × Investors in this round 17 investors had bought by the notice of Jan 4, 2016: 17 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $7 M of $42 M offered; $35 M still to sell
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Charles Evan Ballantyne · Executive Officer Christine M. Klaskin · Executive Officer Garo Armen · Executive Officer, Director Karen H. Valentine · Executive Officer Ozer M. Baysal · Executive Officer Robert M. Stein · Executive Officer Brian M. Corvese · Director Shahzad M. Malik · Director Shalini M. Sharp · Director Timothy R. Wright · Director Tom M. Dechaene · Director · No longer a member of the Board of Directors of the Issuer as of January 1, 2016 Wadih M. Jordan · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by C. Evan Ballantyne, Chief Financial Officer. Source: SEC Form D, newest notice filed Jan 4, 2016. Read the notice at the SEC .
equity SEC Sep 2015 $2 M Private placement after listing $2 to $10 million 2
Antigenics Inc /de/: Private sale, Sep 2015 × Investors in this round 2 investors had bought by the notice of Sep 23, 2015: 2 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $2 M of $2 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Charles Evan Ballantyne · Executive Officer · Chief Financial Officer Christine M. Klaskin · Executive Officer · VP, Finance and Treasurer Garo H. Armen · Executive Officer, Director · President and CEO Karen H. Valentine · Executive Officer · Chief Legal Officer, General Counsel and Secretary Ozer Evan Baysal · Executive Officer · Chief Business Officer Robert R. Stein · Executive Officer · Chief Scientific Officer Brian R. Corvese · Director Shahzad R. Malik · Director Shalini H. Sharp · Director Timothy R. Wright · Director Tom R. Dechaene · Director Wadih R. Jordan · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by C. Evan Ballantyne, Chief Financial Officer. Source: SEC Form D, newest notice filed Sep 23, 2015. Read the notice at the SEC .
equity SEC Feb 2015 $21 M Private placement after listing $10 to $50 million 8
Antigenics Inc /de/: Private sale, Feb 2015 × Investors in this round 8 investors had bought by the notice of Mar 5, 2015: 8 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $21 M of $21 M offered
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Christine Klaskin · Executive Officer Garo Armen · Executive Officer, Director Karen Valentine · Executive Officer Ozer Baysal · Executive Officer Robert Stein · Executive Officer Brian Corvese · Director Shahzad Malik · Director Shalini Sharp · Director Timothy Wright · Director Tom Dechaene · Director Wadih Jordan · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Remarks in the notice On the amounts: “Total amount sold includes warrants to purchase up to 1,400,000 shares of common stock of Agenus Inc. at an exercise price of $5.10 per share.”Signed by Karen H. Valentine, Vice President and General Counsel. Source: SEC Form D, newest notice filed Mar 5, 2015. Read the notice at the SEC .
debt, options SEC Feb 2015 $35 M Private placement after listing $10 to $50 million 1
Antigenics Inc /de/: Private sale, Feb 2015 × Investors in this round 1 investor had bought by the notice of Mar 5, 2015: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $35 M of $35 M offered
Smallest investment taken no minimum stated
What was sold equity Exemption claimed Rule 506(b): a private sale without public advertising; up to 35 buyers may be non-accredited
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
Estimates the notice marks payments to its own people as estimates
The company Corporation, incorporated in Delaware People named in the notice Christine Klaskin · Executive Officer Garo Armen · Executive Officer, Director Karen Valentine · Executive Officer Ozer Baysal · Executive Officer Robert Stein · Executive Officer Brian Corvese · Director Shahzad Malik · Director Shalini Sharp · Director Timothy Wright · Director Tom Dechaene · Director Wadih Jordan · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Karen H. Valentine, Vice President and General Counsel. Source: SEC Form D, newest notice filed Mar 5, 2015. Read the notice at the SEC .
equity SEC Apr 2013 $5 M Private placement after listing $2 to $10 million 3
Antigenics Inc /de/: Private sale, Apr 2013 × Investors in this round 3 investors had bought by the notice of Apr 25, 2013: 3 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $5 M of $5 M offered
Smallest investment taken no minimum stated
What was sold debt, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions none
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Christine Klaskin · Executive Officer Garo Armen · Executive Officer, Director Karen Valentine · Executive Officer Kerry Wentworth · Executive Officer Brian Corvese · Director Shalini Sharp · Director Timothy Wright · Director Tom Dechaene · Director Wadih Jordan · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round No one: the notice names no broker or finder paid to sell it.
Signed by Garo H. Armen, Ph.D., Chief executive officer and chairman of the board. Source: SEC Form D, newest notice filed Apr 25, 2013. Read the notice at the SEC .
debt, options SEC Aug 2009 $10 M Private placement after listing $10 to $50 million 4
Antigenics Inc /de/: Private sale, Aug 2009 × Investors in this round 4 investors had bought by the notice of Aug 13, 2009: 4 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $10 M of $10 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $650,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Christine M Klaskin · Executive Officer Garo H. Armen · Executive Officer, Director Karen Valentine · Executive Officer Kerry A Wentworth · Executive Officer Shalini Sharp · Executive Officer Brian Corvese · Director Hyam I Levitsky, M. D. · Director John Hatsopoulos · Director Timothy Rothwell · Director Timothy Wright · Director Tom Dechaene · Director Wadih Jordan · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Rodman & Renshaw, LLC (CRD 16415) · broker-dealer Rodman & Renshaw, LLC (CRD 16415) · New York, Ny Sold in no state named Signed by Christine M. Klaskin, VP, Finance. Source: SEC Form D, newest notice filed Aug 13, 2009. Read the notice at the SEC .
equity, options SEC Aug 2009 $10 M Private placement after listing $10 to $50 million 1
Antigenics Inc /de/: Private sale, Aug 2009 × Investors in this round 1 investor had bought by the notice of Aug 13, 2009: 1 accredited, none not accredited.
Names not published. The SEC notice gives only the number of investors, and no official source we use names who bought in this round.
What the notice says
Amount sold $10 M of $10 M offered
Smallest investment taken no minimum stated
What was sold equity, options or other rights to buy securities, securities to be acquired by exercising them
Meant to last a year or less
Issuer's revenue Not disclosed
Sales commissions $600,000
Finders' fees none
Paid to its own people none (proceeds used for payments to executives, directors or promoters)
The company Corporation, incorporated in Delaware People named in the notice Christine M Klaskin · Executive Officer Garo H Armen · Executive Officer, Director Karen Valentine · Executive Officer Kerry A Wentworth · Executive Officer Shalini Sharp · Executive Officer Brian Corvese · Director Hyam I Levitsky, M.D · Director John Hatsopoulos · Director Timothy Rothwell · Director Timothy Wright · Director Tom Dechaene · Director Wadih Jordan · Director Executive officers, directors and promoters, as the form asks. Directors of a funded startup are often partners of its investors.
Paid to sell the round Rodman & Renshaw, LLC (CRD 16415) · broker-dealer Rodman & Renshaw, LLC (CRD 16415) · New York, Ny Sold in no state named Signed by Christine M. Klaskin, VP, Finance. Source: SEC Form D, newest notice filed Aug 13, 2009. Read the notice at the SEC .
equity, options SEC